NYSE - Delayed Quote USD

West Pharmaceutical Services, Inc. (WST)

360.43 -7.75 (-2.10%)
At close: April 26 at 4:00 PM EDT
361.15 +0.72 (+0.20%)
After hours: April 26 at 4:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,928,600.00
2,949,800.00
2,886,900.00
2,831,600.00
2,146,900.00
Cost of Revenue
1,840,500.00
1,820,600.00
1,750,700.00
1,655,800.00
1,379,100.00
Gross Profit
1,088,100.00
1,129,200.00
1,136,200.00
1,175,800.00
767,800.00
Operating Expense
423,000.00
421,800.00
375,400.00
415,600.00
348,900.00
Operating Income
665,100.00
707,400.00
760,800.00
760,200.00
418,900.00
Net Non Operating Interest Income Expense
21,000.00
19,000.00
-2,800.00
-7,200.00
-6,800.00
Other Income Expense
-18,600.00
-28,400.00
-78,100.00
-4,100.00
-10,800.00
Pretax Income
667,500.00
698,000.00
679,900.00
748,900.00
401,300.00
Tax Provision
115,100.00
122,300.00
114,700.00
107,200.00
72,500.00
Earnings from Equity Interest Net of Tax
16,300.00
17,700.00
20,700.00
20,100.00
17,400.00
Net Income Common Stockholders
568,700.00
593,400.00
585,900.00
661,800.00
346,200.00
Diluted NI Available to Com Stockholders
568,700.00
593,400.00
585,900.00
661,800.00
346,200.00
Basic EPS
7.67
7.98
7.87
8.89
4.68
Diluted EPS
7.58
7.88
7.73
8.67
4.57
Basic Average Shares
74,050.00
74,300.00
74,400.00
74,400.00
73,900.00
Diluted Average Shares
74,950.00
75,300.00
75,800.00
76,300.00
75,800.00
Total Operating Income as Reported
643,500.00
676,000.00
734,000.00
752,300.00
406,900.00
Total Expenses
2,263,500.00
2,242,400.00
2,126,100.00
2,071,400.00
1,728,000.00
Net Income from Continuing & Discontinued Operation
568,700.00
593,400.00
585,900.00
661,800.00
346,200.00
Normalized Income
586,658.17
619,305.00
608,669.40
667,113.40
356,028.00
Interest Income
29,400.00
28,000.00
5,100.00
1,000.00
1,400.00
Interest Expense
8,400.00
9,000.00
7,900.00
8,200.00
8,200.00
Net Interest Income
21,000.00
19,000.00
-2,800.00
-7,200.00
-6,800.00
EBIT
675,900.00
707,000.00
687,800.00
757,100.00
409,500.00
EBITDA
817,200.00
844,300.00
808,400.00
879,400.00
518,600.00
Reconciled Cost of Revenue
1,840,500.00
1,820,600.00
1,750,700.00
1,655,800.00
1,379,100.00
Reconciled Depreciation
141,300.00
137,300.00
120,600.00
122,300.00
109,100.00
Net Income from Continuing Operation Net Minority Interest
568,700.00
593,400.00
585,900.00
661,800.00
346,200.00
Total Unusual Items Excluding Goodwill
-21,700.00
-31,400.00
-27,400.00
-6,200.00
-12,000.00
Total Unusual Items
-21,700.00
-31,400.00
-27,400.00
-6,200.00
-12,000.00
Normalized EBITDA
838,900.00
875,700.00
835,800.00
885,600.00
530,600.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,741.83
-5,495.00
-4,630.60
-886.60
-2,172.00
12/31/2020 - 3/17/1980

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RMD ResMed Inc.
218.06
+18.89%
 
TFX Teleflex Incorporated
206.71
0.00%
 
RGEN Repligen Corporation
166.58
+0.56%
 
COO The Cooper Companies, Inc.
88.84
-1.21%
 
BDX Becton, Dickinson and Company
231.55
+0.46%
 
ATR AptarGroup, Inc.
143.33
+2.25%
 
HOLX Hologic, Inc.
75.98
+0.36%
 
DIM.PA Sartorius Stedim Biotech S.A.
208.30
+2.41%
 
STVN Stevanato Group S.p.A.
27.54
+0.07%
 
BAX Baxter International Inc.
40.13
-0.25%